🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Gary I. Cohen

ORCID: 0000-0001-7510-8559
MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134”.

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

Journal of Clinical Oncology(2022)10.1200/jco.22.01763
N/A
5.4DataRank · unranked
446 citations

Sandra J. Lee, Bartosz Chmielowski, Ahmad A. Tarhini, Gary I. Cohen, Thach‐Giao Truong +31 more

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002535
N/A
0.520DataRank · unranked
31 citations

Ni Kang, Sandra J. Lee, F. Stephen Hodi, Gary I. Cohen, Omid Hamid +16 more

A phase II study of biomarker-driven early discontinuation of anti–PD-1 therapy in patients with advanced melanoma (PET-Stop): ECOG-ACRIN EA6192.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps9591
N/A
0.241DataRank · unranked
4 citations

Sandra J. Lee, Michael B. Atkins, Terence Z. Wong, Jennifer L. Guerriero, Thomas U. Marron +8 more

Biomarker testing in non-small cell lung cancer (NSCLC): An assessment of current practices in precision oncology in the community setting—A trial of the ECOG-ACRIN cancer research group (EAQ161CD).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.e18649
N/A
0.165DataRank · unranked
2 citations

JoRean D. Sicks, Christine B. Weldon, Gregory J. Tsongalis, Bruce D. Rapkin, Kathryn E. Weaver +11 more

Patient-reported outcomes among patients with resected high-risk melanoma (AJCC7 IIIB, IIIC, M1a, M1b) randomized to low- or high-dose adjuvant Ipilimumab (ipi) versus high-dose interferon alfa-2b (HDI): Health-related quality of life (HRQL) analysis of ECOG-ACRIN E1609.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e22078
N/A
0.104DataRank · unranked
1 citations

Yue Zheng, Sandra J. Lee, F. Stephen Hodi, UMA RAO, Gary I. Cohen +4 more

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of hormone replacement and immunosuppressants, and association with outcome: E1609 study analysis.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.5_suppl.60
N/A
0.104DataRank · unranked
1 citations

Sandra J. Lee, Ni Kang, F. Stephen Hodi, Uma N. M. Rao, Gary I. Cohen +5 more

Unknown primary tumor high-risk melanoma as a unique patient population with distinct prognosis in the adjuvant setting: An ECOG-ACRIN E1609 study analysis.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e22090
N/A
0DataRank · unranked
0 citations

Sandra J. Lee, F. Stephen Hodi, Gary I. Cohen, UMA RAO, Vernon K. Sondak +2 more

The impact of weight loss on physical function and symptoms in overweight or obese breast cancer survivors: results from POWER-remote

Journal of Cancer Survivorship(2021)10.1007/s11764-021-01049-z
N/A
0DataRank · unranked
12 citations

Cesar A. Santa‐Maria, Amanda L. Blackford, David Lim, Ashley Carpenter, Karen L. Smith +6 more

The impact of weight loss on physical function in overweight or obese breast cancer survivors.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.12053
N/A
0DataRank · unranked
3 citations

Cesar Augusto Santa-Maria, Amanda L. Blackford, David Lim, Ashley Carpenter, Karen L. Smith +6 more